Trial · NCT00246519
Pharmacogenomic Evaluation of Antihypertensive Responses
NCT00246519, Phase 4, Completed, University of Florida; results first posted 2013-07-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacogenomic Evaluation of Antihypertensive Responses. Trials, record NCT00246519. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00246519
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacogenomic Evaluation of Antihypertensive Responses
- NCT number
- NCT00246519
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,701 participants, actual
- Lead sponsor
- University of Florida
- Conditions
- Hypertension
- Interventions
- Hydrochlorothiazide, Atenolol
- First posted
- 2005-10-31
- Last updated
- 2018-05-07
- Results first posted
- 2013-07-10
- Limitations and caveats
- The trial has limited number of hypertensive patients of African ancestry, therefore power is limited to those patients.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). | baseline to 18 weeks of treatment | |
| Secondary | Adverse Metabolic Responses | 9-18 weeks of treatment |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). | baseline to 18 weeks of treatment | A total 768 patients had at least monotherapy response data. Of the 386 patients assigned to the atenolol arm, 357 completed both drugs. Of the 382 assigned to the HCTZ arm, 355 completed both drugs. The delta blood pressure below is for patients who completed both drugs. | mmHg | MEAN |
| SECONDARY | Adverse Metabolic Responses | 9-18 weeks of treatment |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). | Atenolol +HCTZ Arm | -12.06 | Standard Deviation 6.96 | mmHg | |
| Blood Pressure Response (Delta BP (After 18 Weeks of Medication - Baseline)). | HCTZ + Atenolol | -13.33 | Standard Deviation 6.80 | mmHg |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atenolol + Hydroclorothiazide (HCTZ) Arm | 442 | |
| Overall Study | STARTED | Hydrochlorothiazide (HCTZ) + Atenolol | 446 | |
| Overall Study | COMPLETED | Atenolol + Hydroclorothiazide (HCTZ) Arm | 386 | |
| Overall Study | COMPLETED | Hydrochlorothiazide (HCTZ) + Atenolol | 382 | |
| Overall Study | NOT COMPLETED | Atenolol + Hydroclorothiazide (HCTZ) Arm | 56 | |
| Overall Study | NOT COMPLETED | Hydrochlorothiazide (HCTZ) + Atenolol | 64 |
Source ClinicalTrials.gov
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Tiredness/Fatigue | General disorders | Atenolol +HCTZ Arm | 21 | 386 | 21 |
| other | Tiredness/Fatigue | General disorders | HCTZ + Atenolol | 25 | 382 | 25 |
| other | Depression | Nervous system disorders | Atenolol +HCTZ Arm | 2 | 386 | 2 |
| other | Depression | Nervous system disorders | HCTZ + Atenolol | 0 | 382 | 0 |
| other | Bradycardia | Cardiac disorders | Atenolol +HCTZ Arm | 1 | 386 | 1 |
| other | Bradycardia | Cardiac disorders | HCTZ + Atenolol | 4 | 382 | 4 |
| other | Dizziness | General disorders | Atenolol +HCTZ Arm | 12 | 386 | 12 |
| other | Dizziness | General disorders | HCTZ + Atenolol | 13 | 382 | 13 |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | Atenolol +HCTZ Arm | 3 | 386 | 3 |
| other | Wheezing | Respiratory, thoracic and mediastinal disorders | HCTZ + Atenolol | 0 | 382 | 0 |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atenolol +HCTZ Arm | ||
| Total, all-cause mortality | HCTZ + Atenolol | ||
| Total, other adverse events | Atenolol +HCTZ Arm | 202 | 386 |
| Total, other adverse events | HCTZ + Atenolol | 190 | 382 |
| Total, serious adverse events | Atenolol +HCTZ Arm | 1 | 386 |
| Total, serious adverse events | HCTZ + Atenolol | 3 | 382 |
Source ClinicalTrials.gov
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01GM074492 | Pharmacogenomic Evaluation of Antihypertensive Responses | JOHNSON, JULIE A.; COOPER-DEHOFF, RHONDA M | UNIVERSITY OF FLORIDA | NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES | 2005 to 2014 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Atenolol +HCTZ Arm vs HCTZ + Atenolol: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00246519
GET https://conductscience.org/api/trials/v1/NCT00246519/events?page=2